



governmentattic.org

"Rummaging in the government's attic"

Description of document:	Dr. Bruce Ivins emails provided by TheEnterpriseReport.com Email Batch Three
Released date:	2009
Posted date:	17-November-2009
Date/date range of documents:	14-June-1999 – 04-May-2000
Source of document:	US Army Medical Research and Materiel Command Fort Detrick, MD
Note:	See following page for other related material available from governmentattic.org

The governmentattic.org web site ("the site") is noncommercial and free to the public. The site and materials made available on the site, such as this file, are for reference only. The governmentattic.org web site and its principals have made every effort to make this information as complete and as accurate as possible, however, there may be mistakes and omissions, both typographical and in content. The governmentattic.org web site and its principals shall have neither liability nor responsibility to any person or entity with respect to any loss or damage caused, or alleged to have been caused, directly or indirectly, by the information provided on the governmentattic.org web site or in this file. The public records published on the site were obtained from government agencies using proper legal channels. Each document is identified as to the source. Any concerns about the contents of the site should be directed to the agency originating the document in question. GovernmentAttic.org is not responsible for the contents of documents published on the website.

THE ENTERPRISE REPORT - TheEnterpriseReport.com

is an online investigative news site founded and published by award-winning Producer/Investigative Journalist Eric Longabardi. The site was named Best Online Website by the LA Press Club in 2008.

Eric Longabardi is a national award winning broadcast producer and investigative journalist with a career spanning nearly two decades. Longabardi has reported extensively on a wide variety issues related to the US Defense Department's research into biological and chemical weapons over the years. He has also reported extensively on the FBI 'Amerithrax' investigation of Dr. Bruce Ivins, the Fort Detrick, Maryland biowarfare scientist the U.S. Department of Justice (DOJ) claims was the person responsible for mailing Anthrax letters which killed five people and sickened 17 others in 2001. Longabardi was the first journalist to disclose the movements and detail the "window of opportunity" of Dr. Ivins on the dates the Anthrax letters were mailed and detail his whereabouts at the Fort Detrick Laboratory where he worked during the dates in question.

The nine batches of emails provided to governmentattic.org were obtained under the Freedom of Information Act (FOIA) by journalist Eric Longabardi beginning on January 22, 2009.

All of this material is available at governmentattic.org.

This file is: Email Batch Three: [DrBruceIvinsEmail_Three.pdf](#) 317 KB

The other available files are:

The Release letter:	DrBruceIvinsEmail_ReleaseLetter.pdf	30 KB
Email Batch One:	DrBruceIvinsEmail_One.pdf	7 MB
Email Batch Two:	DrBruceIvinsEmail_Two.pdf	170 KB
Email Batch Four:	DrBruceIvinsEmail_Four.pdf	176 KB
Email Batch Five:	DrBruceIvinsEmail_Five.pdf	124 KB
Email Batch Six:	DrBruceIvinsEmail_Six.pdf	130 KB
Email Batch Seven:	DrBruceIvinsEmail_Seven.pdf	145 KB
Email Batch Eight:	DrBruceIvinsEmail_Eight.pdf	221 KB
Email Batch Nine:	DrBruceIvinsEmail_Nine.pdf	329 KB
All above material in one PDF:	DrBruceIvinsEmail_All.pdf	6.2 MB

From: [Ivins, Bruce E Dr USAMRIID](#)
To: (b) (6)
Subject: FW: Titers for B97-05 sera
Date: Friday, January 28, 2000 2:33:35 PM
Attachments: JB992402.xls

>-----Original Message-----

>From: (b) (6)
>Sent: Thursday, January 27, 2000 5:31 PM
>To: Ivins, Bruce E Dr USAMRIID
>Subject: RE: Titers for B97-05 sera

>

> Thats your data attached. Any problems let me know. The 2 low positive "saline" controls were on a plate filled with negatives so I didn't see an evident problem with the results.

>

>Have fun,

(b) (6)

>

>-----Original Message-----

>From: Ivins, Bruce E Dr USAMRIID
>Sent: Wednesday, January 26, 2000 3:46 PM
>To: (b) (6)
>Subject: RE: Titers for B97-05 sera

>

>Yes, please! Thanks, (b) (6)

>

>- Bruce

>

> -----Original Message-----

> From: (b) (6)
> Sent: Wednesday, January 26, 2000 1:52 PM
> To: Ivins, Bruce E Dr USAMRIID
> Subject: RE: Titers for B97-05 sera

>

> It just so happens that I am running them as I answer this. Expect results sometime tomorrow. Did you want the probit titer like last time?

>

(b) (6)

(6)

> -----Original Message-----

> From: Ivins, Bruce E Dr USAMRIID
> Sent: Wednesday, January 26, 2000 11:16 AM
> To: (b) (6)
> Subject: Titers for B97-05 sera

>

(b) (6)

> Have the Anti-PA ELISA titers for B97-05 rabbit sera been run yet? If not, do you know about when they might be done?

>

> Thanks!

>

> - Bruce

From: [Ivins, Bruce E Dr USAMRIID](#)
To: (b) (6)
Subject: (b) (6) s Contract
Date: Wednesday, February 02, 2000 3:47:44 PM

Hi, (b) (6)
(b) (6) I think I told you that when (b) (6) contract is up (I believe it's up sometime between the 12th and the 15th of July) I would like to get (b) (6) a 10% raise. Can you tell me what I need to do in order to get (b) (6) the raise? How much more money do I need to add to the contract? (I think (b) (6) present contract cost us \$34,720.00.) What do I need to do at this end to get (b) (6) the raise besides adding more money? Do I need to change the contract to get more money taken (b) (6) out each pay period? If we could talk about this to get it straightened out, I would appreciate it.

- Bruce

From: [Ivins, Bruce E Dr USAMRIID](#)
To: (b) (6)
Subject: CRM Contract with (b) (6)
Date: Thursday, February 03, 2000 9:06:57 AM

Hi, (b) (6)
(b) (6) This correspondence is in reference to (b) (6) my contract technician since 15 July, 1999, with Clinical research Management, Delivery Order 0004, DAMD 17-98-D-0026.

Since (b) (6) began working with us last year (b) (6) has gained valuable experience in my laboratory (b) (6) and is currently performing quite well as a technician. We wish to compensate (b) (6) for (b) (6) abilities in the lab and make certain that we retain (b) (6), since the job (b) (6) holds requires vaccination against a number of diseases, and the vaccination process takes several months to accomplish. Thus, we wish to raise (b) (6) salary by 10%. This would also bring (b) (6) salary up closer to that which is being made by individuals (b) (6) holding similar positions at other nearby research facilities.

I talked with (b) (6) at Clinical Research Management (b) (6) this morning, and (b) (6) asked me to "get the ball rolling" on this by contacting you. Whatever else I need to do on this please let me know. (b) (6) said that you would contact (b) (6) on the matter.

Thanks, (b) (6) for your help.
(b) (6)

- Bruce Ivins
USAMRIID Bacteriology Division
(b) (6)

From: [Ivins, Bruce E Dr USAMRIID](#)
To: (b) (6)
Subject: FW: VERY HOT ITEM FROM MG PARKER: FW: Topics of possible assistance
Date: Wednesday, February 09, 2000 3:15:53 PM
Importance: High
Sensitivity: Private

-----Original Message-----

From: (b) (6)
Sent: Wednesday, February 09, 2000 1:04 PM
To: (b) (6); (b) (6)
(b) (6) Ivins,
Bruce E Dr USAMRIID; (b) (6)
Subject: VERY HOT ITEM FROM MG PARKER: FW: Topics of possible assistance
Importance: High
Sensitivity: Private

I just received a call from MG Parker regarding this action and the need for a very rapid response to the requests that are enunciated by (b) (6) from BioPort. I will have a follow on message to suggest that we get as many of us together before COB today and strategize this. Others are welcome to attend. I will hold it in (b) (6) office. Right now I have a briefing to do.

Please call (b) (6) to indicate if you will be available around 1600 hrs today .

(b) (6)

-----Original Message-----

From: Parker, John S MG USAMRMC
Sent: Wednesday, February 09, 2000 12:49 PM
To: (b) (6)
Subject: FW: Topics of possible assistance
Importance: High
Sensitivity: Private

(b) (6) need this worked ASAP. John

-----Original Message-----

From: (b) (6)
Sent: Tuesday, February 01, 2000 9:02 PM
To: 'Parker, John S MG USAMRMC'; (b) (6)
Cc: (b) (6)
Subject: RE: Topics of possible assistance

O.K. Will stand by for further word.

(b) (6)

-----Original Message-----

From: Parker, John S MG USAMRMC (b) (6)
Sent: Tuesday, February 01, 2000 7:45 PM
To: (b) (6)
Cc: (b) (6)

Subject: RE: Topics of possible assistance

(b) (6) I will get back to you. I am staffing these possibilities with my laboratories. John

-----Original Message-----

From: (b) (6)
Sent: Monday, January 24, 2000 10:23 AM
To: john.parker (b) (6)
Cc: (b) (6)
Subject: Topics of possible assistance

MG Parker,

When you visited BioPort recently, you asked that I outline areas where your Command could assist in the furtherance of the AVA Biologics License Application (BLA) approval process and the resolution of issues with doses in inventory made previous to the renovation.

We received a complete Response Letter from FDA on December 29, 1999, have completely reviewed the letter and developed a work plan to address issues raised in the letter. From these activities I have generated the following list of possible participation and facilitation.

1. Evaluation of the final product:
 - a. Develop and qualify assay to identify the presence of bio-active LF, if any;
 - b. Serve as a site for inter-laboratory comparison of the present guinea pig potency test;
 - c. Develop methods for quantitative elution of antigens from aluminum hydroxide adjuvant and characterization of the eluted antigens;
 - d. More fully develop and validate a surrogate animal model of efficacy and evaluate new lots and lots in inventory with that model.
2. Validate and transfer to BioPort the Elisa assays for PA, LF and EF antigens.
3. Serve as subject matter experts, providing technical, consultative advice on:
 - a. Process stream (intermediate fractions) characterization;
 - b. Final product characterization;
 - c. Method development and validation of characterization methods;
 - d. Specifically, utilization and interpretation of SDS-PAGE and Western Blot evaluations of process streams.
4. Prepare, characterize and qualify reagents to be utilized in evaluation of the AVA manufacturing process and final AVA product.
5. Develop and qualify an AVA reference vaccine.
6. Develop and validate a n alternative potency test that is more reproducible and correlative of results found with the rabbit and primate vaccination /challenge studies.

Parts of items 1-4 can have a positive impact on the BLA approval process. Items 5 and 6 are probably future activities. There are also areas of infrastructure support that could be considered such as assistance in corporate safety programming, regulatory affairs and improved coordination of adverse event investigation, documentation and compliance. Perhaps our respective staffs could meet soon to determine areas where assistance would be provided and to develop joint objectives and work plans in the selected areas.

From: [Ivins, Bruce E Dr USAMRIID](#)
To: (b) (6)
Subject: FW: VERY HOT ITEM FROM MG PARKER: FW: Topics of possible assistance
Date: Wednesday, February 09, 2000 2:37:59 PM
Importance: High
Sensitivity: Private

Hi, (b) (6)

(6) I told you that General Parker wants us to solve Bio-Port's problems with AVA. Below is the list. UGH!! We are having a meeting today starting at 4 pm in the Commander's office. Oh, well, maybe they'll order pizza if the meeting goes on for awhile. :)

- Bruce

Subject: Topics of possible assistance

MG Parker,

When you visited BioPort recently, you asked that I outline areas where your Command could assist in the furtherance of the AVA Biologics License Application (BLA) approval process and the resolution of issues with doses in inventory made previous to the renovation.

We received a complete Response Letter from FDA on December 29, 1999, have completely reviewed the letter and developed a work plan to address issues raised in the letter. From these activities I have generated the following list of possible participation and facilitation.

1. Evaluation of the final product:
 - a. Develop and qualify assay to identify the presence of bio-active LF, if any;
 - b. Serve as a site for inter-laboratory comparison of the present guinea pig potency test;
 - c. Develop methods for quantitative elution of antigens from aluminum hydroxide adjuvant and characterization of the eluted antigens;
 - d. More fully develop and validate a surrogate animal model of efficacy and evaluate new lots and lots in inventory with that model.
2. Validate and transfer to BioPort the Elisa assays for PA, LF and EF antigens.
3. Serve as subject matter experts, providing technical, consultative advice on:
 - a. Process stream (intermediate fractions) characterization;
 - b. Final product characterization;
 - c. Method development and validation of characterization methods;
 - d. Specifically, utilization and interpretation of SDS-PAGE and Western Blot evaluations of process streams.
4. Prepare, characterize and qualify reagents to be utilized in evaluation of the AVA manufacturing process and final AVA product.
5. Develop and qualify an AVA reference vaccine.
6. Develop and validate a n alternative potency test that is more

reproducible and correlative of results found with the rabbit and primate vaccination /challenge studies.

Parts of items 1-4 can have a positive impact on the BLA approval process. Items 5 and 6 are probably future activities. There are also areas of infrastructure support that could be considered such as assistance in corporate safety programming, regulatory affairs and improved coordination of adverse event investigation, documentation and compliance. Perhaps our respective staffs could meet soon to determine areas where assistance would be provided and to develop joint objectives and work plans in the selected areas.

From: [Ivins, Bruce E Dr USAMRIID](#)
To: (b) (6)
Subject: FW: Rabbit animal protocol-potency test and meeting
Date: Friday, February 11, 2000 9:17:06 AM
Attachments: [Rabbit protocol-rPA_potency01.doc](#)

(b) (6)

Here is (b) (6) animal protocol for potency testing/efficacy testing and finding a surrogate marker of immunity. Please let us know after you read this what would be a good time to meet on it.

Thanks.

- Bruce

>-----Original Message-----

>From: (b) (6)
>Sent: Thursday, January 06, 2000 2:03 PM
>To: Ivins Bruce E Dr USAMRIID; (b) (6)

>Subject: Rabbit animal protocol-potency test

>

>

>

>

>Attached is the final version of the animal protocol
>for the potency assay & efficacy study of rPA.

From: [Ivins, Bruce E Dr USAMRIID](#)
To: (b) (6)
Subject: RE: "UFRs"
Date: Friday, February 11, 2000 8:38:18 AM
Attachments: [Unfunded Requirement for FY00.doc](#)

Here it is, (b) (6). If you need more experimental detail, I can give it to you. The investigators involved would basically be (b) (6) and myself. (b) (6) (phagocytosis and molecular biology studies), (b) (6) (aerosol challenge studies) and a veterinary pathologist would also be involved.

- Bruce

>-----Original Message-----

>From: (b) (6)
>Sent: Friday, February 11, 2000 8:27 AM
>To: Ivins, Bruce E Dr USAMRIID
>Subject: RE: "UFRs"

>

>Bruce,

>

>Sounds fine - write 'er up. Use the short "blurby" format found in the attachments that I sent you. I did get a clarification from (b) (6) - the \$\$ requested CAN'T be used for equipment.

>

>

>

>

>-----

>From: Ivins, Bruce E Dr USAMRIID
>Sent: Thursday, February 10, 2000 3:22 PM
>To: (b) (6)
>Subject: RE: "UFRs"

>

>(b) (6)

>I want to submit a UFR for doing some research on "atypical" (exceptionally virulent) strains of B. anthracis. Basically it would be looking at the strains from several perspectives (molecular, physiological, immunological, pathogenic, etc.) It would involve several of the anthrax researchers in the division. Any assistance you can provide would be great.

>

>Thanks!

>

>- Bruce

>

>

>

>

>-----Original Message-----

>From: (b) (6)
>Sent: Thursday, February 10, 2000 8:35 AM
>To: (b) (6)

>

>Ivins, Bruce E Dr

USAMRIID; (b) (6)

>

>

>Cc: (b) (6)

>Subject: "UFRs"

>

>Folks:

>

> (b) (6) has indicated to us that supplemental \$\$ may be available for Unfunded Requirements (UFRs). This may amount to potentially several million \$\$ to be distributed among all the bio and chem defense labs. (b) (6) thought that this might be a good time to submit new UFRs from the respective Divisions. I've attached a guidance sheet which outlines the identification of a task as a "UFR". If you decide that you have a UFR which applies directly to ongoing research projects in your lab (current year expenditures), please submit a short write-up to me by 16 Feb. Use a format similar to the ones that are presented in the FY 99 UFR list, which I've also attached. After a review by (b) (6) and myself, I'll consolidate and forward them to (b) (6). A major (and rather puzzling) restriction is that the requested \$\$ CANNOT be used for purchasing equipment (just supplies), but as you'll see in the FY 99 list, there are several pieces of equipment specified. I'm trying to resolve this conflict with (b) (6), and will get back to you all, once I have an answer. For now, assume that equipment purchases are o.k. (if the work can't be accomplished w/o them). If you have any questions, please give me a shout or stop by. TNX. (b)

>

> << File: UFRGuidFY00.doc >> << File: UFR's '99 >>

>

>

>

From: [Ivins, Bruce E Dr USAMRIID](#)
To: (b) (6)
Subject: RE: MPL-AF
Date: Wednesday, February 16, 2000 3:43:01 PM

Sure, (b) (6)! Yes, I did!
- Bruce (b) (6)

>-----Original Message-----

>From: (b) (6) USAMRIID
>Sent: Wednesday, February 16, 2000 3:35 PM
>To: Ivins, Bruce E Dr USAMRIID
>Subject: MPL-AF

>

>Bruce,

>

>My F1-V protocol has finally completed the circuit and I am ready to actually get some real work done. I'm in the process of ordering some mice - once those come in I'll be needing the MPL-AF to mix with the F1-V. For the first dose I'll need about 700 microliters of the stuff - should I just call you a day or so beforehand and come by and get it?

>

>Thanks!

>

>BTW, did you enjoy the Anthrax-no digests I sent you? Interesting to know what we're up against.

>

>(b) (6)

>

>(b) (6)

(b) (6)

>(b) (6)

>U.S. Army Medical Research Institute of Infectious Disease
>1425 Porter St. Ft. Detrick
>Frederick, MD 21702-5011

(b) (6)

(b) (6)

>

From: [Ivins, Bruce E Dr USAMRIID](#)
To: (b) (6)
Subject: Draft DTO
Date: Monday, February 21, 2000 10:22:24 AM
Attachments: [DRAFT DTO.doc](#)

(b) (6)

Here is a draft DTO for anthrax that you requested.

Bruce

From: [Ivins, Bruce E Dr USAMRIID](#)
To: (b) (6)
Subject: FW: Contract
Date: Wednesday, February 23, 2000 12:12:49 PM

If we intend to have an international anthrax conference in 2001, the contract needs to be signed!! (b) (6)
I believe that you have the contract. Can we please get this taken care of before the whole thing falls through, and we owe the ASM for a conference that they worked on?

- Bruce

-----Original Message-----

From: (b) (6)
Sent: Wednesday, February 23, 2000 10:41 AM
To: (b) (6)
Cc: Bruce Ivins (E-mail)
Subject: RE: Contract

(b) (6) I can't sign it until the Army comes to a final agreement with ASM.
(W)ould you please extend that deadline another six weeks? I know its a lot to ask, but the agreement must make its way up the ranks at Ft. Detrick.

I am copying our contact there, Bruce Ivins, to let him know that you are awaiting word. Thanks for your patience.

> -----Original Message-----

> From: (b) (6)
> Sent: Wednesday, February 23, 2000 9:55 AM
> To: (b) (6)
> Subject: Contract

>
>
>

> Hi (b) (6), just a reminder that we were expecting the contract by February
> 18 (b) (6)
> If you would please sign and return by Friday, I would appreciate it
> greatly...any questions, please advise. We look forward to hosting your
> group
> . Best wishes,

(b) (6)

From: [Ivins, Bruce E Dr USAMRIID](#)
To: (b) (6)
Subject: RE: Contract
Date: Wednesday, February 23, 2000 12:26:17 PM

Sure, (b) (6) I'm sorry that it's taken so long. I'll keep on (b) (6) to get it signed. If (b) (6) misplaced it, I'll let you know (b) (6) and you can send us (FAX or email) a new copy. (b) (6)

Thanks again,

- Bruce

-----Original Message-----

From: (b) (6)
Sent: Wednesday, February 23, 2000 12:08 PM
To: 'Ivins, Bruce E Dr USAMRIID'
Subject: RE: Contract

Thanks, Bruce!

> -----Original Message-----

> From: Ivins, Bruce E Dr USAMRIID (b) (6)
> Sent: Wednesday, February 23, 2000 12:13 PM
> To: (b) (6)

> Subject: FW: Contract

>
> If we intend to have an international anthrax conference in 2001, the
> contract needs to be signed!! (b) (6) I believe that you have the contract.
> Can (b) (6)
> we please get this taken care of before the whole thing falls through, and
> we owe the ASM for a conference that they worked on?

> - Bruce

>

>

>

>

> -----Original Message-----

> From: (b) (6)
> Sent: Wednesday, February 23, 2000 10:41 AM
> To: (b) (6)
> Cc: Bruce Ivins (E-mail)
> Subject: RE: Contract

>

>

> (b) (6) I can't sign it until the Army comes to a final agreement with ASM.
> (b) (6) Would you please extend that deadline another six weeks? I know its a lot
> to ask, but the agreement must make its way up the ranks at Ft. Detrick.

>

> I am copying our contact there, Bruce Ivins, to let him know that you are
> awaiting word. Thanks for your patience.

>

> > -----Original Message-----

> > From: (b) (6)
> > Wednesday, February 23, 2000 9:55 AM

> > To: (b) (6)

> > Subject: Contract

> >

> >

> >

> > Hi (b) [REDACTED] ust a reminder that we were expecting the contract by February

> > 18(a)

> > If you would please sign and return by Friday, I would appreciate it

> > greatly...any questions, please advise. We look forward to hosting

> your

> > group

> > . Best wishes,

> >

(b) (6) [REDACTED]

> >

From: [Ivins, Bruce E Dr USAMRIID](#)
To: (b) (6)
Subject: RE: multiagent vaccine study
Date: Monday, February 28, 2000 8:13:33 AM

We have space in B3 for the guinea pigs at any time.

- Bruce

>-----Original Message-----

>From: (b) (6) USAMRIID
>Sent: Thursday, February 24, 2000 12:53 PM
>To: (b) (6); Ivins, Bruce E Dr USAMRIID;
(b) (6)
>Subject: multiagent vaccine study
>
>We are ready to schedule the multiagent vaccine study. There are two experiments that need to be scheduled.
>
>Experiment 1 - prime boost study for Ebola and anthrax
> We would like to start this experiment as soon as possible. There are 9 groups of 6 guinea pigs (54 total) that will need to be challenged with Ebola 8-12 (most likely 12) weeks after beginning vaccination. There are 6 groups of 6 guinea pigs (36 total) that will need to be challenged with anthrax.
>
>Experiment 2 - DNA multiagent vaccine for Ebola, Marburg, anthrax, and VEE
> We would like to start this experiment 2-4 weeks after beginning the first experiment. I realize that the challenge portion of the first experiment will need to be complete to allow for suite space for the challenge of the animals in this second experiment. Challenges needed are as follows:
> 1. Ebola - 3 groups of 6 (18 total)
> 2. Marburg - 3 groups of 6 (18 total)
> 3. anthrax - 4 groups of 6 (24 total)
> 4. VEE - 4 groups of 6 (24 total)
>
>(b) (6) the critical thing I need to know from you is when you can accomidate suite space for the Ebola and Marburg challenges.
>
>Dr. Ivins, the critical thing I need to know from you is when you can accomidate suite space for the anthrax challenges.
>
>The availability of the suites needs to be at the same time.
>
>I want to thank you in advance for your cooperation. I know that these are large studies and require a large amount of space. If you need anything form me, please let me know. I appreciate your efforts.
>
>Best regards,
(b) (6)

From: [Ivins, Bruce E Dr USAMRIID](#)
To: (b) (6)
Subject: RE: multiagent vaccine study
Date: Wednesday, March 01, 2000 10:43:41 AM

(b)

(b) (6) is all prepared to do the ELISA assays, and (b) (6) has done them previously. My suggestion - to make it easier for you - would be to have (b) (6) group do these. Why not contact (b) (6) and ask (b) (6)

- Bruce

>-----Original Message-----

>From: (b) (6) USAMRIID
>Sent: Wednesday, March 01, 2000 10:37 AM
>To: Ivins, Bruce E Dr USAMRIID
>Subject: RE: multiagent vaccine study

>

>Dear Bruce,

> I have some answers for your questions below. They are as follows:

>

>1. We don't have the dates yet. I just got with (b) (6) yesterday and (b) (6) said that we can start immediately. I am ordering the Hartley animals today. I hope to start within the next 2 weeks. The prime boost will be started first and we will start the second experiment 2 weeks later.

>

>2. Experiment 1 is all gene gun except the AVA and TC83 control.

>

>3. Group 6 is the licensed AVA vaccine. I have been assuming that you have some of this. I apologize for not asking earlier, there has been a lot to coordinate on this. If you have a better idea for a control for this, we are open to it.

>

>4. We are planning to keep all animals will be on the cold side for all vaccinations.

>

>5. I have spoken with VET MED numerous times to coordinate this with them. I have spoken with (b) (6). I have worked with (b) (6) techs) numerous times. They will be the primary assistance form VET MED on this.

>

>6. I can do these if you wish and was planning to do so. I will need some antigen for the ELISA's (the more I type here the more I realize that there are several reagents I will need for you to provide, I apologize for not clearing this with you earlier. this study has been a logistical nightmare!). If you prefer (b) (6) do these assays, that is fine with me also.

>-----

>1. Yes 30 total and 6 negative controls.

>

>2. see above.

>

>Thanks for all your efforts on this. You have helped a great deal. I appreciate your questions as they have helped me be better prepared.

>

>Best regards,

(b)

(6)

>

>-----
> From: Ivins, Bruce E Dr USAMRIID
> Sent: Wednesday, March 1, 2000 10:16 AM
> To: (b) (6)
> Subject: RE: multiagent vaccine study

>

> Dear (b) (6)
> Questions about the study (Experiment 1) with respect to anthrax :
> 1. Do you have the dates of immunization and challenge yet?
> 2. For group 4, do these critters only get DNA vaccine by gene gun (no other anthrax
> vaccines)?
> 3. For group 6, I presume that these animals get only the licensed human anthrax
> vaccine?
> 4. Are these animals going to be "cold" until challenge?
> 5. Have the Vet Med personnel who will bleed these animals been identified and
> contacted?
> 6. Who will be doing the anthrax anti-PA ELISAs? (b) (6)

> Questions about Experiment 2 with respect to anthrax:
> 1. It looks like a total of 30 animals will be vaccinated for anthrax. Correct?
> 2. See questions 4-6 above.

> General comments: It would be easiest if these animals could stay "cold" until challenge.
> We have plenty of space in B-3 for them, and we have licensed anthrax vaccine, PA, Ribi adjuvant, and
> aluminum hydroxide.

> - Bruce

> -----Original Message-----

> From: (b) (6)
> Sent: Thursday, February 24, 2000 12:53 PM
> To: (b) (6) Ivins, Bruce E Dr

> (b) (6)
> Subject: multiagent vaccine study

> We are ready to schedule the multiagent vaccine study. There are two experiments that
> need to be scheduled.

> Experiment 1 - prime boost study for Ebola and anthrax

> We would like to start this experiment as soon as possible. There are 9 groups of 6
> guinea pigs (54 total) that will need to be challenged with Ebola 8-12 (most likely 12) weeks after
> beginning vaccination. There are 6 groups of 6 guinea pigs (36 total) that will need to be challenged
> with anthrax.

> Experiment 2 - DNA multiagent vaccine for Ebola, Marburg, anthrax, and VEE

> We would like to start this experiment 2-4 weeks after beginning the first experiment.
> I realize that the challenge portion of the first experiment will need to be complete to allow for suite
> space for the challenge of the animals in this second experiment. Challenges needed are as follows:

- > 1. Ebola - 3 groups of 6 (18 total)
- > 2. Marburg - 3 groups of 6 (18 total)
- > 3. anthrax - 4 groups of 6 (24 total)
- > 4. VEE - 4 groups of 6 (24 total)

> (b) (6) the critical thing I need to know from you is when you can accomidate suite
> space for the Ebola and Marburg challenges.

> Dr. Ivins, the critical thing I need to know from you is when you can accomidate suite space
> for the anthrax challenges.

> The availability of the suites needs to be at the same time.

> I want to thank you in advance for your cooperation. I know that these are large studies
> and require a large amount of space. If you need anything form me, please let me know. I appreciate
> your efforts.

> Best regards,

>
>

(b) (6)

From: [Ivins, Bruce E Dr USAMRIID](#)
To: (b) (6)
Subject: FW: Contract
Date: Monday, March 06, 2000 3:57:33 PM
Attachments: anthraxtemplate.doc

Here it is, (b) (6) Thanks!

- Bruce

-----Original Message-----

From: (b) (6)
Sent: Wednesday, February 23, 2000 12:31 PM
To: 'Ivins, Bruce E Dr USAMRIID'
Subject: RE: Contract

I've attached it just in case.

<<anthraxtemplate.doc>>

> -----Original Message-----

> From: Ivins, Bruce E Dr USAMRIID [SMTP:Bruce.Ivins@usamriid.gov] (b) (6)
> Sent: Wednesday, February 23, 2000 12:26 PM
> To: (b) (6)
> Subject: RE: Contract

>
> Sure (b) (6) I'm sorry that it's taken so long. I'll keep on (b) (6) o get it
> signed. If (b) (6) misplaced it, I'll let you know and you can (b) (6) send us (FAX
> or (b) (6)
> email) a new copy.

> Thanks again,

> - Bruce

> -----Original Message-----

> From: (b) (6)
> Sent: Wednesday, February 23, 2000 12:08 PM
> To: 'Ivins, Bruce E Dr USAMRIID'
> Subject: RE: Contract

> Thanks, Bruce!

> -----Original Message-----

> > From: Ivins, Bruce E Dr USAMRIID
> [SMTP:Bruce.Ivins@usamriid.gov] (b) (6)
> > Sent: Wednesday, February 23, 2000 12:13 PM
> > To: (b) (6)

> > Cc: (b) (6)

> > Subject: FW: Contract

> >
> > If we intend to have an international anthrax conference in 2001, the
> > contract needs to be signed!! (b) (6), I believe that you have the contract.
> > Can (b) (6)
> > we please get this taken care of before the whole thing falls through,

> and
> > we owe the ASM for a conference that they worked on?
> >

> > - Bruce
> >
> >

> > -----Original Message-----

> > From: (b) (6)
> > Sent: Wednesday, February 23, 2000 10:41 AM
> > To: (b) (6)
> > Cc: Bruce Ivins (E-mail)
> > Subject: RE: Contract
> >

> > (b) (6) I can't sign it until the Army comes to a final agreement with
> ASM
> > Would you please extend that deadline another six weeks? I know its a
> lot
> > to ask, but the agreement must make its way up the ranks at Ft. Detrick.
> >
> > I am copying our contact there, Bruce Ivins, to let him know that you
> are
> > awaiting word. Thanks for your patience.
> >

> > > -----Original Message-----

> > > From: (b) (6)
> > > Sent: Wednesday, February 23, 2000 9:55 AM
> > > To: (b) (6)
> > > Subject: Contract
> > >

> > > H (b) (6) just a reminder that we were expecting the contract by
> February (b) (6)
> > > 18...
> > > If you would please sign and return by Friday, I would appreciate it
> > > greatly...any questions, please advise. We look forward to hosting
> > your
> > > group
> > > . Best wishes,
> > >
> > > (b) (6)
> > >

From: [Ivins, Bruce E Dr USAMRIID](#)
To: (b) (6)
Subject: RE: Policy question
Date: Monday, March 06, 2000 11:10:37 AM

Hi, (b) (6) So nice to hear from you, but shame on you for getting (b) (6) "in a family way!" (Just kidding, of course.) Here at USAMRIID, pregnant women are not allowed in biocontainment suites, at least the BL-3 suites where they work with B. anthracis. Talk to you later!

- Bruce

-----Original Message-----

From: (b) (6)
Sent: Monday, March 06, 2000 8:53 AM
To: 'Bruce.Ivins@'(b) (6)
Subject: Policy question

Dear Bruce,

Hi! I think you know I am doing this spell at CDC helping (I hope) them to retrieve lost low-tech anthrax skills. I believe (b) (6) conveyed my good wishes 10 days ago in DC.

Can you tell me whether there is a policy in place in USAMRIID regarding pregnant women working with B. anthracis? This is assuming that, at the time they learn they are pregnant, their vaccination status is OK.

Despite "retirement" from (b) (6), I have a string of papers/chapter demands hanging round my neck. Working on these I constantly marvel at how productive you have been over the 16 years (I think) I have known you. Citations of your work always constitute great strings in my references. (b) (6) have done extremely well also, of course. It seems to remain a great team up there.

Enough flattery, I must get back to work!

Usual best wishes,

(b) (6)